Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

doi:10.1128/JVI.72.11.8943-8951.1998

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

Journal of virology - 1 Nov 1998

Lewis J, Balfe P, Arnold C, Kaye S, Tedder R S, McKeating J A

Abstract excerpt

We monitored the primary humoral response to human immunodeficiency virus type 1 infection and showed that, in addition to antibodies to p24 and gp41, antigens which form the basis of most diagnostic assays, the response included a significant antibody response directed to the gp120 region of the...

Topics

Amino Acid Sequence
Antigenic Variation
Chimera
Cytopathogenic Effect, Viral
HIV Antibodies
HIV Antigens
HIV Core Protein p24
HIV Envelope Protein gp120
HIV Seropositivity
HIV-1
Humans
Molecular Sequence Data
Neutralization Tests
Open Reading Frames
Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 9765439
DOI: 10.1128/JVI.72.11.8943-8951.1998
PMCID: PMC110311

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9765439-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptors, CCR5

Time Factors

Viremia